Q1 2023 Results

Company overview Innovation: Pipeline overview Cardiovascular Financial review Financial performance Immunology ianalumab - BAFF-R inhibitor Conclusions NCT05639114 SIRIUS-SLE 1 (CVAY736F12301) Systemic lupus erythematosus Indication Phase Phase 3 Patients 406 Primary Outcome Measures Arms Intervention Proportion of participants on monthly ianalumab achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4) [ Time Frame: Week 60 ] Experimental: lanalumab s.c. monthly Experimental: lanalumab s.c. quarterly Placebo Comparator: Placebo s.c. monthly Target Patients Patients with active systemic lupus erythematosus (SLE) Readout Milestone(s) 2027 Publication TBD 59 Investor Relations | Q1 2023 Results Appendix Innovation: Clinical trials Neuroscience Oncology ianalumab - BAFF-R inhibitor NCT05624749 SIRIUS-SLE 2 (CVAY736F12302) References Abbreviations Other Indication Systemic lupus erythematosus Phase Phase 3 Patients 280 Primary Outcome Measures Proportion of participants achieving Systemic Lupus Erythematosus Responder Index -4 (SRI-4) [ Time Frame: Week 60 ] Arms Experimental: ianalumab s.c. monthly Intervention Placebo Comparator: placebo s.c. monthly Target Patients Patients with active systemic lupus erythematosus (SLE) Readout Milestone(s) 2027 Publication TBD NOVARTIS | Reimagining Medicine

View entire presentation